Navigation Links
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Date:4/24/2008

through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
11. John Marshall and Kevin McGuinness Appointed to Ellex Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Due to a misstatement posted by the Family Resource ... Center, LLC ( ASCTC ) was reported as an entity ... benefit ALS patients. Because of ASCTC's exclusive focus on ... therapeutic applications, FRC listed ASCTC as one of several alternatives ... not to support research that requires the death of human ...
(Date:8/28/2014)... SPIE Fellow Glenn Boreman, Professor and ... and Director of the Center for Optoelectronics and Optical ... and co-founder and Chairman of the Board of Plasmonics, ... Vice President of SPIE, the international society for optics ... recent election results at the Annual General Meeting of ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... -- Theoretical work done at the Department of Energy,s ... understanding an unexpected magnetism between two dissimilar materials. ... special significance for the design of future electronic devices ... of ORNL,s Materials Science and Technology Division. The work ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today ... September 30, 2010 after the market closes on Wednesday, November ... Chief Executive Officer, Kent Griffin, President, and Greg N. Lubushkin, ... 9:00 a.m. Pacific Time on Thursday, November 4, 2010 to ...
... England, Oct. 18 A 67-year-old female patient with ... tumor was small and it rode up and down ... doctors saw on their therapy system,s imaging equipment was ... Trust was able to utilize its Symmetry™ motion ...
Cached Biology Technology:ORNL theorist part of team that discovers unexpected magnetism 2BioMed Realty Trust to Report 2010 Third Quarter Results 2Clinicians Use Advanced Radiotherapy Imaging Techniques from Elekta to More Accurately Visualize Moving Tumors in Patients with Lung Cancer 2Clinicians Use Advanced Radiotherapy Imaging Techniques from Elekta to More Accurately Visualize Moving Tumors in Patients with Lung Cancer 3
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... that an expansion of marine protected areas is needed ... According to investigators from the Wildlife Conservation Society ... focused on saving the largest numbers of species, often ... and difficult-to-replace ecological functions. , Many vital ... species that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... , , , , ... Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of ... entry into a Loan and Security Agreement with Terry M. Giles, ... In connection with, and as required by the Loan, on ...
... , , , , ... Reportlinker.com announces that a new market research report is available in ... Signature Verification Market , , ... worldwide markets for Dynamic Signature Verification in US$ Thousands. The market ...
... , WALL, N.J., Sept. 14 / PRNewswire-FirstCall / ... a leader in finger-based biometric identification and wireless public safety solutions, ... Advisor and Consultant to the company. Tom will play a major ... the government and commercial markets. , , (Logo: ...
Cached Biology News:Pacific Biometrics Completes $4 Million Debt Financing 2Pacific Biometrics Completes $4 Million Debt Financing 3Pacific Biometrics Completes $4 Million Debt Financing 4Pacific Biometrics Completes $4 Million Debt Financing 5Reportlinker Adds World Dynamic Signature Verification Market Report 2Reportlinker Adds World Dynamic Signature Verification Market Report 3Reportlinker Adds World Dynamic Signature Verification Market Report 4Reportlinker Adds World Dynamic Signature Verification Market Report 5Reportlinker Adds World Dynamic Signature Verification Market Report 6Reportlinker Adds World Dynamic Signature Verification Market Report 7Reportlinker Adds World Dynamic Signature Verification Market Report 8Reportlinker Adds World Dynamic Signature Verification Market Report 9BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 2BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 3BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 4
... was developed using a protein engineering approach that ... pocket of wild-type DNase I. These changes markedly ... The result is a versatile enzyme that has ... ability to maintain at least 50% of peak ...
Request Info...
MAb to Mouse MHC Class I H-2Kd...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: